Business
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
COPENHAGEN, Denmark & UTRECHT, Netherlands, September 29, 2025--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab, which is in Phase 3 development, for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 b
About this update from Genmab A/s
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1301,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/be60d24bd4c5f11f34bff551b7547888"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nOpVtPGuoCSNBbGUtlV5Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/be60d24bd4c5f11f34bff551b7547888","width":960,"height":280},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8LOzaaZSWHHvy2ii0DFxGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/be60d24bd4c5f11f34bff551b7547888","width":1200,"height":350}},"lazy":false},{"type":"text","content":"Company Announcement","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion","length":140,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio","length":124,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Transaction anticipated to be accretive to EBITDA by end of 2029","length":64,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT","length":83,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":411,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark & UTRECHT, Netherlands, September 29, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab, which is in Phase 3 development, for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion. The transaction has been unanimously approved by the Boards of Directors of both companies. A wholly owned subsidiary of Genmab ("Purchaser") will commence a tender offer for 100% of Merus’ common s...